Trubion slumps after Pfizer kills lead RA drug program

Shares of Seattle-based Trubion Pharmaceuticals (TRBN) slumped after Pfizer announced that it was dumping the development program for its lead rheumatoid arthritis drug. TRU-015 had been Trubion's first shot at a best-in-class CD20 therapy that could compete with Rituxan. But in a mid-stage clinical trial--in which TRU-015 was combined with methotrexate--the drug failed to provide a statistically superior to the placebo plus methotrexate, which registered an unusually high response. "Given...